Clinical Trial Update: Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports on the efficacy and safety of M281 in adults with Warm Autoimmune Hemolytic Anemia, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• M281

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Warm Autoimmune Hemolytic Anemia | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING